Yale Study on the Evidence of Ketamine Therapy and Spravato Treatments

Immediate Release: Evidence Supporting Ketamine Therapy & SPRAVATO® (Esketamine)

First Published by Your North Wellness on the Ketmine Warrington Blog.

This article discusses the evidence supporting Ketamine Therapy & SPRAVATO® (Esketamine) for treatment-resistant depression (TRD). It highlights a Yale-led study comparing the effectiveness of IV ketamine and SPRAVATO® nasal spray in a real-world clinical setting.

See Also: How Safe is Ketamine Therapy?

Key Points:

• Study Details: Conducted by Yale School of Medicine, in collaboration with Emory University, the University of Michigan, and three community sites.
• Funding: Supported by a $12.6 million grant from the Patient-Centered Outcomes Research Institute (PCORI).
• Participants: 400 patients with TRD will be randomly assigned to IV ketamine or SPRAVATO®.
• Data Collection: Researchers will analyze treatment response, tolerability, and long-term effects.
• FDA Approval & Insurance Challenges: SPRAVATO® is FDA-approved, but IV ketamine is not, leading to insurance coverage disparities.
• Ketamine Registry Proposal: Yale researchers advocate for a registry to standardize dosage, frequency, and patient outcomes.

The study aims to provide critical insights into the effectiveness of IV ketamine vs. SPRAVATO®, shaping future mental health treatments and insurance policies.

For more details, visit Ketamine Warrington.